Skip to main navigation Skip to search Skip to main content

Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease

  • Marion Lenglet*
  • , Florence Robriquet
  • , Klaus Schwarz
  • , Carme Camps
  • , Anne Couturier
  • , David Hoogewijs
  • , Alexandre Buffet
  • , Samnatha, J.L. Knight
  • , Sophie Gad
  • , Sophie Couvé
  • , Franck Chesnel
  • , Mathilde Pacault
  • , Pierre Lindenbaum
  • , Sylvie Job
  • , Solenne Dumont
  • , Thomas Besnard
  • , Marine Cornec
  • , Helene Dreau
  • , Melissa Pentony
  • , Erika Kvikstad
  • Sophie Deveaux, Nelly Burnichon, Sophie Ferlicot, Mathias Vilaine, Jean-Michaël Mazzella, Fabrice Airaud, Céline Garrec, Laurence Heidet, Sabine Irtan, Elpis Mantadakis, Karim Bouchireb, Klaus-Michael Debatin, Richard Redon, Stephane Bezieau, Brigitte Bressac-de Paillerets, Bin Tean Teh, François Girodon, Maria Luigia Randi, Maria Caterina Putti, Vincent Bours, Richard van Wijk, Joachim R. Göthert, Antonis Kattamis, Nicolas Janin, Celeste Bento, Jenny C Taylor, Yannick Arlot-Bonnemains, Stéphane Richard, Anne Paule Gimenez-Roqueplo, Holger Cario, Betty Gardie
*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

Chuvash polycythemia is an autosomal recessive form of erythrocytosis associated with a homozygous p.Arg200Trp mutation in the von Hippel-Lindau (VHL) gene. Since this discovery, additional VHL mutations have been identified in patients with congenital erythrocytosis, in a homozygous or compound-heterozygous state. VHL is a major tumor suppressor gene, mutations in which were first described in patients presenting with VHL disease, which is characterized by the development of highly vascularized tumors. Here, we identify a new VHL cryptic exon (termed E19) deep in intron 1 that is naturally expressed in many tissues. More importantly, we identify mutations in E19 in 7 families with erythrocytosis (1 homozygous case and 6 compound-heterozygous cases with a mutation in E19 in addition to a mutation in VHL coding sequences) and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, we show that the mutations induced a dysregulation of VHL splicing with excessive retention of E19 and were associated with a downregulation of VHL protein expression. In addition, we demonstrate a pathogenic role for synonymous mutations in VHL exon 2 that altered splicing through E2-skipping in 5 families with erythrocytosis or VHL disease. In all the studied cases, the mutations differentially affected splicing, correlating with phenotype severity. This study demonstrates that cryptic exon retention and exon skipping are new VHL alterations and reveals a novel complex splicing regulation of the VHL gene. These findings open new avenues for diagnosis and research regarding the VHL-related hypoxia-signaling pathway.

Original languageEnglish
Pages (from-to)469-483
Number of pages15
JournalBlood
Volume132
Issue number5
DOIs
Publication statusPublished - 2 Aug 2018

Fingerprint

Dive into the research topics of 'Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease'. Together they form a unique fingerprint.

Cite this